These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

138 related articles for article (PubMed ID: 23010853)

  • 1. Pharmacokinetics of eribulin mesylate in patients with solid tumors and hepatic impairment.
    Devriese LA; Witteveen PO; Marchetti S; Mergui-Roelvink M; Reyderman L; Wanders J; Jenner A; Edwards G; Beijnen JH; Voest EE; Schellens JH
    Cancer Chemother Pharmacol; 2012 Dec; 70(6):823-32. PubMed ID: 23010853
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacokinetics of eribulin mesylate in cancer patients with normal and impaired renal function.
    Tan AR; Sarantopoulos J; Lee L; Reyderman L; He Y; Olivo M; Goel S
    Cancer Chemother Pharmacol; 2015 Nov; 76(5):1051-61. PubMed ID: 26433580
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Eribulin mesylate in patients with refractory cancers: a Phase I study.
    Mukohara T; Nagai S; Mukai H; Namiki M; Minami H
    Invest New Drugs; 2012 Oct; 30(5):1926-33. PubMed ID: 21887501
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A phase 1 study of eribulin mesylate (E7389), a novel microtubule-targeting chemotherapeutic agent, in children with refractory or recurrent solid tumors: A Children's Oncology Group Phase 1 Consortium study (ADVL1314).
    Schafer ES; Rau RE; Berg S; Liu X; Minard CG; D'Adamo D; Scott R; Reyderman L; Martinez G; Devarajan S; Reid JM; Fox E; Weigel BJ; Blaney SM
    Pediatr Blood Cancer; 2018 Aug; 65(8):e27066. PubMed ID: 29719113
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Phase I study of eribulin mesylate administered once every 21 days in patients with advanced solid tumors.
    Tan AR; Rubin EH; Walton DC; Shuster DE; Wong YN; Fang F; Ashworth S; Rosen LS
    Clin Cancer Res; 2009 Jun; 15(12):4213-9. PubMed ID: 19509146
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Eribulin, Child-Pugh score, and liver-function tests: lessons from pivotal breast cancer studies 301 and 305.
    Macpherson IR; He Y; Palmieri C
    Breast Cancer Res; 2021 Mar; 23(1):33. PubMed ID: 33736675
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacokinetics of eribulin mesylate in patients with solid tumours receiving repeated oral rifampicin.
    Devriese LA; Witteveen PE; Wanders J; Law K; Edwards G; Reyderman L; Copalu W; Peng F; Marchetti S; Beijnen JH; Huitema AD; Voest EE; Schellens JH
    Br J Clin Pharmacol; 2013 Feb; 75(2):507-15. PubMed ID: 22803519
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A phase I study of eribulin mesylate (E7389), a mechanistically novel inhibitor of microtubule dynamics, in patients with advanced solid malignancies.
    Goel S; Mita AC; Mita M; Rowinsky EK; Chu QS; Wong N; Desjardins C; Fang F; Jansen M; Shuster DE; Mani S; Takimoto CH
    Clin Cancer Res; 2009 Jun; 15(12):4207-12. PubMed ID: 19509177
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacodynamics (PD) and pharmacokinetics (PK) of E7389 (eribulin, halichondrin B analog) during a phase I trial in patients with advanced solid tumors: a California Cancer Consortium trial.
    Morgan RJ; Synold TW; Longmate JA; Quinn DI; Gandara D; Lenz HJ; Ruel C; Xi B; Lewis MD; Colevas AD; Doroshow J; Newman EM
    Cancer Chemother Pharmacol; 2015 Nov; 76(5):897-907. PubMed ID: 26362045
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Phase 1 combination study of eribulin mesylate with trastuzumab for advanced or recurrent human epidermal growth factor receptor 2 positive breast cancer.
    Mukai H; Saeki T; Shimada K; Naito Y; Matsubara N; Nakanishi T; Obaishi H; Namiki M; Sasaki Y
    Invest New Drugs; 2015 Feb; 33(1):119-27. PubMed ID: 25242374
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The European medicines agency review of eribulin for the treatment of patients with locally advanced or metastatic breast cancer: summary of the scientific assessment of the committee for medicinal products for human use.
    Pean E; Klaar S; Berglund EG; Salmonson T; Borregaard J; Hofland KF; Ersbøll J; Abadie E; Giuliani R; Pignatti F
    Clin Cancer Res; 2012 Sep; 18(17):4491-7. PubMed ID: 22829199
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Eribulin mesylate pharmacokinetics in patients with solid tumors receiving repeated oral ketoconazole.
    Devriese LA; Mergui-Roelvink M; Wanders J; Jenner A; Edwards G; Reyderman L; Copalu W; Peng F; Marchetti S; Beijnen JH; Schellens JH
    Invest New Drugs; 2013 Apr; 31(2):381-9. PubMed ID: 22555773
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Phase 1 dose-finding and pharmacokinetic study of eribulin-liposomal formulation in patients with solid tumours.
    Evans TRJ; Dean E; Molife LR; Lopez J; Ranson M; El-Khouly F; Zubairi I; Savulsky C; Reyderman L; Jia Y; Sweeting L; Greystoke A; Barriuso J; Kristeleit R
    Br J Cancer; 2019 Feb; 120(4):379-386. PubMed ID: 30679780
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Phase I study of the halichondrin B analogue eribulin mesylate in combination with cisplatin in advanced solid tumors.
    Koczywas M; Frankel PH; Synold TW; Lenz HJ; Mortimer JE; El-Khoueiry AB; Gandara DR; Cristea MC; Chung VM; Lim D; Reckamp KL; Lau DH; Doyle LA; Ruel C; Carroll MI; Newman EM
    Br J Cancer; 2014 Dec; 111(12):2268-74. PubMed ID: 25349975
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Eribulin: rediscovering tubulin as an anticancer target.
    Jimeno A
    Clin Cancer Res; 2009 Jun; 15(12):3903-5. PubMed ID: 19509144
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A phase 1b/2, open-label, dose-escalation, and dose-confirmation study of eribulin mesilate in combination with capecitabine.
    Twelves C; Anthoney A; Savulsky CI; Guo M; Reyderman L; Cresti N; Semiglazov V; Timcheva C; Zubairi I; Morrison R; Plummer R; Evans TRJ
    Br J Cancer; 2019 Mar; 120(6):579-586. PubMed ID: 30783204
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A phase I, open-label, single-arm study for QT assessment of eribulin mesylate in patients with advanced solid tumors.
    Lesimple T; Edeline J; Carrothers TJ; Cvitkovic F; Darpo B; Delord JP; Léna H; Penel N; Edwards GJ; Law K; Wanders J; Kristensen A; Reyderman L
    Invest New Drugs; 2013 Aug; 31(4):900-9. PubMed ID: 23143778
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Mass balance study of [¹⁴C]eribulin in patients with advanced solid tumors.
    Dubbelman AC; Rosing H; Jansen RS; Mergui-Roelvink M; Huitema AD; Koetz B; Lymboura M; Reyderman L; Lopez-Anaya A; Schellens JH; Beijnen JH
    Drug Metab Dispos; 2012 Feb; 40(2):313-21. PubMed ID: 22041109
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Anti-tumor mechanism and clinical efficacy of Eribulin (Halaven®), a new microtubulin inhibitor approved for treatment of metastatic breast cancer].
    Koyama N; Tokunaga T; Ogasawara W; Murakami M; Yamashita Y
    Nihon Yakurigaku Zasshi; 2011 Nov; 138(5):209-17. PubMed ID: 22075465
    [No Abstract]   [Full Text] [Related]  

  • 20. Activity of eribulin mesylate in patients with soft-tissue sarcoma: a phase 2 study in four independent histological subtypes.
    Schöffski P; Ray-Coquard IL; Cioffi A; Bui NB; Bauer S; Hartmann JT; Krarup-Hansen A; Grünwald V; Sciot R; Dumez H; Blay JY; Le Cesne A; Wanders J; Hayward C; Marreaud S; Ouali M; Hohenberger P;
    Lancet Oncol; 2011 Oct; 12(11):1045-52. PubMed ID: 21937277
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.